Lymphoma, Large Cell, Diffuse Clinical Trial
Official title:
Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transplantation (ASCT)
The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to 65 years with poor prognosis CD 20 Diffuse Large B-Cell lymphoma
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00532259 -
CT-011 MAb in DLBCL Patients Following ASCT
|
Phase 2 | |
| Terminated |
NCT00322218 -
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
|
Phase 3 | |
| Completed |
NCT00436280 -
Chemotherapy for Participants With Lymphoma
|
Phase 2 |